South Korean medical AI company VUNO announced on the 12th that it will acquire shares and investment securities worth USD 2.4 million (KRW 3.4 billion) in Coreline Soft, a company specializing in chest imaging technology.  

VUNO explained that this acquisition is part of its plan to transfer technology related to its chest CT solution, VUNO Med®-LungCT™ (LungCT), to Coreline Soft. The company intends to use most of the acquisition funds to cover the cost of the LungCT transfer.  

Regarding the decision to transfer its LungCT-related business, VUNO stated that it was a strategic move to focus on its core strengths. CEO Yeha Lee said, “Going forward, we will concentrate more on ‘preventive medical AI,’ with a particular emphasis on our flagship product, the cardiac arrest prediction solution VUNO Med®-DeepCARS™. We are committed to strengthening our overseas business foundation and will put our full effort into this goal.” The decision reflects VUNO’s strategy to optimize its operations for continued growth.  

VUNO also expects to generate synergies from the deal, given Coreline Soft’s strong analytical capabilities in chest imaging diagnostics. CEO Yeha Lee emphasized, “The global medical AI industry has moved beyond its early stages and is now entering a phase of rapid growth. If Korea’s top AI companies continue to refine their core businesses, they will be able to expand their competitiveness in the global market while creating valuable synergies.”